Medical News
Raltegravir 1200 mg once daily as maintenance therapy in vir...
AIDS Res. Ther.
RAL 1200 mg qd as part of a maintenance triple therapy showed a high efficacy in virologically suppressed HIV-1...
18 Jan 2022
HIV Disease Dynamics and Markers of Inflammation and CNS Inj...
JAIDS
Biomarkers of CNS inflammation, immune activation, and neuronal injury peak early and then decline during acute HIV...
17 Jan 2022
Incidence and Clearance of Anal High-risk Human Papillomavir...
Nature
A nadir CD4 + count < 200 cells/mm3 significantly reduced the clearance of hrHPVs other than HPV16 (aHR 0.39, 95...
11 Jan 2022
Causes of Death and Associated Factors Over a Decade of Foll...
BMC Infect Dis
Incidence of HIV-related mortality was higher than that of non-HIV-related mortality, even in more recent years,...
11 Jan 2022
eCMEs
Key Trials
Impact of Azithromycin on ARES in Children with HIV and Chronic Lung Disease
The present study is the post hoc analysis of BREATHE trial, The analysis aimed to explored the risk factors for acute respiratory exacerbations in...
Daily PrEP Verses on Demand PrEP Regimen Coverage CLAI for MSM
The present study determined the impacts of oral tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg (TDF/FTC) on demand verses daily PrEP ...
BRAAVE Trial: Efficacy of Switching to STR of B/F/TAF vs Continuing on Regimen of 2 NRTIs and a Third Agent in Virologically Suppressed HIV Adults
BRAAVE study is the randomized phase 3 study evaluating efficacy and safety of switching to fixed-dose combination of B/F/TAF vs continuing...
Safety and Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in People with HIV
The present study evaluated safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine in people with HIV (PLHIV) in a well characterised UK cohort....
Our Publications
Antiretroviral-based Prevention Strategies in HIV
Today, antiretroviral therapy (ART) is not only known to keep HIV-infected patients alive but is also being harnessed as a strategy to prevent...
Antiretroviral Therapy – Current Recommendations
Advances in the treatment of HIV infection has resulted in a dramatic shift, from a deadly infectious disease to a chronic manageable condition....
Datasheet: Lopinavir and Ritonavir (40mg/10mg) Oral Pellets
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This datasheet contains the entire...
Fast Facts: Lopinavir and Ritonavir (40 mg/10 mg) Oral Pellets
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This booklet contains information about...
Patient Education
Live Healthier, Live Longer
This publication features commonly asked questions by HIV patients regarding HIV therapy, drug side-effects, Do’s and Don’ts while on HIV treatment....
Living with Hope
This publication features common questions which arise in HIV patients mind regarding HIV, diagnosis, transmission, treatment and drug side effects. ...
Slide Library
HIV - HCV Coinfection
This slide set covers the epidemiology, disease progression and management of HIV-HCV coinfection in the era of directly acting antivirals available...
HIV - Pre-exposure Prophylaxis (PrEP): Guidance on PrEP Use
PrEP is the use of an antiretroviral medication by HIV-negative individuals to prevent them from acquiring HIV. These slides give an overview on the...
HIV- Post-exposure Prophylaxis (PEP)
Post-exposure prophylaxis (PEP) is the method of preventing exposures of HIV to blood and body fluids and it is considered to be the most important...
Isoniazid Preventive Therapy in HIV Infection
HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection....
Infographics
Currently there is no content under this category.
Poll
Which is your preferred 3rd drug in a first-line regimen?
Efavirenz 600
Efavirenz 400
Dolutegravir
Total votes: 6